Xizang Haisco Pharmaceutical Group Co Ltd (002653) — Net Asset Quality Index
Xizang Haisco Pharmaceutical Group Co Ltd (002653) has a Net Asset Quality Index of 58.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥7.21 Billion minus total liabilities of CN¥2.99 Billion yields net assets of CN¥4.23 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Xizang Haisco Pharmaceutical Group Co Lt (002653) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xizang Haisco Pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2024)
This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 58.6%, representing net assets of CN¥4.23 Billion against total assets of CN¥7.21 Billion CNY. See Xizang Haisco Pharmaceutical Group Co Lt (002653) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Xizang Haisco Pharmaceutical Group Co Lt stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 61.8% | CN¥4.20 Billion | CN¥6.80 Billion | CN¥2.60 Billion | ▼ -0.9 pp |
| 2023 | 62.7% | CN¥4.17 Billion | CN¥6.65 Billion | CN¥2.48 Billion | ▲ +10.9 pp |
| 2022 | 51.8% | CN¥3.13 Billion | CN¥6.05 Billion | CN¥2.91 Billion | ▼ -6.5 pp |
| 2021 | 58.3% | CN¥2.92 Billion | CN¥5.01 Billion | CN¥2.09 Billion | ▲ +1.2 pp |
| 2020 | 57.1% | CN¥2.85 Billion | CN¥5.00 Billion | CN¥2.14 Billion | ▲ +9.9 pp |
| 2019 | 47.2% | CN¥2.38 Billion | CN¥5.04 Billion | CN¥2.66 Billion | ▲ +1.5 pp |
| 2018 | 45.7% | CN¥1.99 Billion | CN¥4.37 Billion | CN¥2.37 Billion | ▼ -2.3 pp |
| 2017 | 48.0% | CN¥1.97 Billion | CN¥4.11 Billion | CN¥2.14 Billion | ▼ -13.0 pp |
| 2016 | 61.0% | CN¥2.26 Billion | CN¥3.71 Billion | CN¥1.45 Billion | ▼ -5.9 pp |
| 2015 | 66.8% | CN¥2.16 Billion | CN¥3.23 Billion | CN¥1.07 Billion | ▼ -6.5 pp |
| 2014 | 73.3% | CN¥2.11 Billion | CN¥2.87 Billion | CN¥767.55 Million | ▼ -5.1 pp |
| 2013 | 78.4% | CN¥1.93 Billion | CN¥2.46 Billion | CN¥530.24 Million | ▼ -9.3 pp |
| 2012 | 87.7% | CN¥1.71 Billion | CN¥1.95 Billion | CN¥238.49 Million | ▲ +0.8 pp |
| 2011 | 87.0% | CN¥767.76 Million | CN¥882.70 Million | CN¥114.95 Million | ▲ +15.0 pp |
| 2010 | 71.9% | CN¥453.09 Million | CN¥629.88 Million | CN¥176.79 Million | ▲ +33.2 pp |
| 2009 | 38.7% | CN¥135.17 Million | CN¥349.39 Million | CN¥214.22 Million | ▼ -22.1 pp |
| 2008 | 60.8% | CN¥214.95 Million | CN¥353.69 Million | CN¥138.73 Million | — |